Zelira’s ZLT-L-007 Outperforms Lyrica, Boosts HOPE® 1 Funding

• ZLT-L-007 shows superior pain relief and sleep improvement over Lyrica in diabetic neuropathy
• Full conversion of US$3.25 million convertible notes into HOPE® 1 SPV equity strengthens capital structure
• Secured $650,000 non-dilutive loan to support R&D and optimize FY25 tax incentives
• Q4 FY2025 operational expenses decreased due to payment timing, net cash outflow of $384k